SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (906)3/26/2014 2:27:31 PM
From: tejek  Read Replies (1) | Respond to of 930
 
But is the fact that there is no near term gratification worth a 38% plunge?

The argument is that if there was significant efficacy the trial would have ended here instead of going to completion. Given the company's prospects in 2014, I think the sell off is overdone...but then that's pretty typical for selloffs.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News